key: cord-0902576-dgjqhg73
authors: Toda, Masataro; Yoshifuji, Ayumi; Fujii, Kentaro; Komatsu, Motoaki; Kato, Ai; Tamura, Ikue; Sugi, Wataru; Ryuzaki, Munekazu
title: Patients with hemodialysis-induced hypoxemia had a poor prognosis of COVID-19
date: 2022-05-20
journal: Ren Replace Ther
DOI: 10.1186/s41100-022-00408-5
sha: 8c04d99e3c61c5cd95146c78f746840fc939b144
doc_id: 902576
cord_uid: dgjqhg73

BACKGROUND: We experienced that some hemodialysis (HD) patients with coronavirus disease 2019 (COVID-19) exacerbated hypoxemia during HD. Though HD-induced hypoxemia has been reported, there have been no reports of HD-induced hypoxemia in patients with COVID-19 and its effect on prognosis of COVID-19. METHODS: Eleven HD patients admitted with COVID-19 from August 2020 to April 2021 were classified into the patients whose oxygen demand increased by more than 3 L/min with mask during HD (worsened group, n = 5) and others (not-worsened group, n = 6). The background, laboratory findings, severity of COVID-19 and prognosis were compared between the two groups. In addition, blood gases were measured before and after dialysis among HD patients admitted with COVID-19 on April 2021 (n = 3). RESULTS: There were no significant differences in backgrounds, except for a higher proportion of diabetes mellitus in worsened group (p = 0.04). Although laboratory findings were not significantly different on admission day, albumin and LDH levels 7 days after admission were significantly lower and higher in worsened group, respectively (p = 0.03 and < 0.01). The severity of COVID-19 and survival rate were significantly worse in worsened group (p = 0.01 and 0.03). The alveolar-arterial oxygen pressure difference (Aa-DO(2)) opened during HD in a patient with HD-induced hypoxemia, but did not open in patients without HD-induced hypoxemia. CONCLUSIONS: There is a close relationship among HD-induced hypoxemia and poor prognosis of COVID-19. The HD-induced hypoxemia of patients with COVID-19 may be caused by ventilation/perfusion mismatching. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41100-022-00408-5.

Since the first case of coronavirus disease 2019 in December 2019, more than hundreds of million people infected COVID-19 worldwide. Hemodialysis (HD) patients are at a much higher risk of COVID-19 than the general population and have nearly 20% mortality rate of COVID-19 (1) . This is considered to be attributed to dysfunction of both innate and adaptive immune systems and number of comorbid underlying diseases of HD patients (2) . Among HD patients with COVID-19, older age, male, longer duration of dialysis, diabetic mellitus (DM), and cardiovascular disease were identified as predictors of poor prognosis (3) . However, it is unclear whether HD itself affects severity and prognosis of HD patients with COVID-19.

As the clinical symptoms of COVID-19 rapidly become severe due to "cytokine storm, " which means a systemic high inflammation caused by uncontrolled overproduction of cytokines, immunomodulators including steroids and various cytokine receptor inhibitors have been used to suppress cytokine storm in patients with COVID-19 (4) . Generally, dialysis activates various immune pathways, such as complement cascade, neutrophils, monocytes, inducing systemic inflammation (2) . Since HD patients with COVID-19 also showed increased cytokine production after dialysis compared to before, especially in critical cases (5) , HD itself may provoke systemic inflammation, worsening COVID-19 prognosis.

We experienced that some HD patients hospitalized with COVID-19 had exacerbation of respiratory condition during HD. While some HD-induced hypoxemia in non-COVID-19 patients has been reported (6, 7) , there are no reports on patients with COVID-19. To best of our knowledge, this is the first study to examine the mechanism why some patients with COVID-19 worsened their respiratory condition during HD and its effect on prognosis.

Eleven HD patients admitted to our hospital with COVID-19 from August 2020 to April 2021. Before February 2021, all patients were treated with standard therapy (dexamethasone and antiviral therapy). After February 2021, patients who underwent high-flow nasal cannula (HFNC) oxygen therapy were treated with tocilizumab (TCZ) (8 mg/kg) and methylprednisolone (mPSL) (500 mg/day [≤ 75 kg], 1000 mg/day [> 75 kg]) for 3 days in addition to standard therapy (Additional file 1: Table S1 ). We classified them into the patients whose oxygen demand increased by more than 3 L/min with mask during HD (worsened group) (n = 5) and patients whose oxygen demand did not increase during HD (notworsened group) (n = 6). The background, laboratory findings (albumin, CRP, LDH, ferritin, D-dimer and lymphocyte count), severity of COVID-19 and prognosis were compared. The severity of COVID-19 was categorized according to the following condition; "Severe" as a case with a SpO 2 less than 94% on room air at sea level and required oxygen therapy; "Critical" as a case requiring HFNC or intubation (patients were intubated when 10 L/min of oxygen was required to maintain SpO 2 above 94%, but if intubation was not consented, they were placed on HFNC). Changes in oxygen demand and LDH were evaluated after hospitalization in five patients of worsened group (CRP was strongly suppressed by TCZ, and an inadequate indicator of COVID-19 pneumonia severity, therefore LDH was used as a marker of COVID-19 severity and lung injury (8)). Furthermore, blood gases were measured before and after dialysis in patients admitted on April 2021 (n = 3), as an additional study.

Median values were compared using the Mann-Whitney U test. Frequencies between groups were compared using Fisher's exact test or the Chi-square test. Statistical significance was set at p < 0.05. Statistical analysis was performed using GraphPad Prism 9.

Clinical course of patients whose oxygen demand increased during dialysis Figure 1 showed the clinical course of 5 patients whose oxygen demand increased by more than 3 L/min with mask during post-hospitalization dialysis. Patient 1 whose oxygen demand greatly increased during dialysis on day 8 after admission placed on HFNC on day 11 and then, he died 32 days later. Patient 2 whose oxygen demand increased during dialysis on day 3 after admission was intubated on day 6 and died one day later. Patient 3 whose oxygen demand increased during dialysis day 8 after admission was placed on HFNC on the same day. His respiratory condition improved, and he was weaned HFNC off on day 20. However, his oxygen demand increased during dialysis on day 21 and 24, so he was placed on HFNC again after dialysis on day 31 and then, he died two days later. Patient 4 whose oxygen demand greatly increased during dialysis day 13 after admission was placed on HFNC on day 15. His respiratory condition improved, and he was weaned HFNC off on day 22 with a favorable clinical outcome. Among these four patients, LDH levels tended to increase with elevated oxygen demand. Patient 5 whose oxygen demand increased during dialysis on day 2 after admission improved his condition and no longer needed the oxygen demand with decrease trend of LDH levels ( Fig. 1 ).

As the backgrounds, there were no significant differences in age, sex, body mass index, dialysis vintage, causes of end-stage renal disease and the presence of cancer between two groups. However, the proportion of DM in the worsened group was significantly higher than in the non-worsened group (p = 0.04) ( Table 1) . Although no significant differences were observed in laboratory findings on admission day, albumin and LDH levels 7 days after admission were significantly lower and higher in worsened group than in not-worsened group, respectively (p = 0.03 and < 0.01). In addition, day 7 after admission, CRP, ferritin and D-dimer levels tended to be higher and lymphocyte count level tended to be lower in worsened group (Table 1, Fig. 2 ). In worsened group, 4 out of 5 patients demanded 10 L/min of oxygen with mask to maintain SpO 2 above 94% and were placed on HFNC or intubation, while no one in not-worsened group (p = 0.01). Therefore, the severity of COVID-19 is significantly worse in the worsened group than in notworsened group (p = 0.01). Further, worsened group had significantly lower survival rate than not-worsened group (p = 0.03) ( Table 1) .

Among three patients, blood gases were measured before and after dialysis, only one patient whose oxygen demand with mask increased more than 3 L/min and PO 2 /FiO 2 ratio worsened from 359.4 to 169.6 mmHg during dialysis. The blood gas findings showed that the alveolar-arterial oxygen pressure difference (Aa-DO 2 ) opened from 79.2 to 227.3 in a patient with oxygen demand increased, but the Aa-DO 2 almost did not change in other two patient whose oxygen demand did not increase. The pH increased to alkalosis, but there was no pCO 2 retention in all patients ( Table 2 ).

In this study, we experienced that respiratory condition worsened during HD in patients with severe or critical COVID-19, and clarified the close relationship between HD-induced hypoxemia and poor prognosis of COVID-19.

Our data demonstrated that the worsened group had a significantly higher severity and required HFNC more frequently than the not-worsened group (Fig. 1,  Table 1 ). We hypothesized that two processes may be involved in the mechanism by which HD hypoxemia is more likely to occur in severe to critical COVID-19 patients. Firstly, the dialysis membranes induce recruitment of neutrophils and monocytes, which release pro-inflammatory cytokines, such as interleukin 1, interleukin 6 (IL-6), and tumor necrosis factor-α. In fact, IL-6 after HD was reported to be elevated compared to that before HD in COVID-19 patients, especially in critical cases (5) . Secondly, HD activates complement cascade both alternative pathway and lectin pathway due to absorbing inhibitors of these pathways by dialysis membranes (2) . Through these processes, dialysis membranes and activated complement recruit neutrophils and monocytes into blood vessels, and then, these cells accumulate and occlude the pulmonary vascular bed, causing ventilation/perfusion mismatching, leading to HD-induced hypoxemia. In addition, the ventilation/perfusion mismatching is also considered to be caused by lung interstitial edema resulted from increased pulmonary vascular permeability due to activated complement and neutrophilic adhesion. Furthermore, in severe COVID-19, the prevalence of alveolar-capillary microthrombi is nine times higher than in influenza. In COVID-19, D-dimer is reported as the most useful marker for thrombosis (9) , and the worsened group tended to have higher D-dimer levels on admission and 7 days after admission than the not-worsened group. One of the mechanisms of this is Fig. 1 Clinical course of patients whose oxygen demand increased during dialysis. Five patients whose oxygen demand increased by more than 3 L/min with mask during post-hospitalization dialysis. Patient 1-4 were intubated or placed on HFNC after their oxygen demand greatly increased during dialysis. Among these four patients, LDH levels tended to increase with elevated oxygen demand. Patient 5 whose oxygen demand once increased during dialysis improved his condition and no longer needed the oxygen demand with decrease trend of LDH levels. HFNC; high-flow nasal cannula, LDH; lactate dehydrogenase platelet activation by activated neutrophils via neutrophil extracellular traps (NETs) and platelet-monocyte aggregates forming microthrombi. Also, the induction of endothelial adhesion molecules, neutrophils, monocytes and platelet activation by complement activation is related above mechanism (10, 11) . Therefore, the induction of neutrophils, monocytes and complement activation by dialysis may cause pulmonary vascular microthrombosis resulting in the ventilation/perfusion mismatching. According to our results of blood gases before and after dialysis, the Aa-DO 2 opened from 79.2 to 227.3 in a patient with oxygen demand increased, but the Aa-DO 2 almost did not change in patients whose oxygen demand did not increase, suggesting that the ventilation/perfusion mismatching causes HD-induced hypoxemia. In addition, there was a significantly higher proportion of DM patients in the worsened group compared with the not-worsened group. It was reported that IL-6 after HD was elevated in DM patients compared to before HD (12, 13) . It could be assumed that COVID-19 patients with DM were more prone to inflammation due to dialysis, contributing to ventilation/perfusion mismatching. On the other hand, the other causes of HD-induced hypoxemia include hypoventilation-induced hypoxemia due to increase in pH by bicarbonate influx . 2 Between-group comparisons of laboratory data. There were no significant differences in laboratory findings on Day 0. However, albumin and LDH levels on Day 7 were significantly lower and higher in worsened group than in not-worsened group, respectively (p = 0.03 and < 0.01).

In addition, CRP, ferritin and D-dimer levels were tended to be higher and lymphocyte count level was tended to be lower in worsened group on Day 7. N; not-worsened group, W; worsened group, Alb; albumin, LDH; lactate dehydrogenase, CRP; C-reactive protein, Day 0; admission day, Day 7; 7 days after admission during HD, sleep apnea when they sleep during HD, decreased cardiac output due to decreased blood volume, and exacerbation of cardiogenic pulmonary edema by supine position (7) have been reported. However, our study shows pH increased, but pCO 2 did not retain in both patients with and without increased oxygen demand. In addition, there is no patient who slept or markedly decreased blood pressure during HD or had cardiac failure. These facts indicate that the HD-induced hypoxemia of patients with COVID-19 may be caused by ventilation/perfusion mismatching. COVID-19 causes the excessive immune response to SARS-CoV-2 in severe to critical condition, which is called cytokine storm, leading to multiple organ failure including impaired respiratory function. (4). In our study, patients with HD-induced hypoxemia (worsened group) had significantly worse severity of COVID-19 and lower survival rates compared to not-worsened group (Table 1 , Fig. 2 ). Therefore, hypoxemia during dialysis may be a predictor of poor prognosis in HD patients with COVID-19. It has been reported that the induction of inflammation by HD is a poor prognostic factor of COVID-19 (5) , suggesting that the hypoxemia as a clinical outcome of HD-induced inflammation may be considered a poor prognostic factor as well. Furthermore, in COVID-19, LDH levels are positively associated with systemic inflammation (8) , and high LDH and low albumin have been reported as predictors of poor prognosis in HD patients with COVID-19. In this study, the worsened group had significantly higher LDH and lower albumin levels than the not-worsened group on day 7 of admission, even though there was no significant difference at admission (14) (15) . Although it is not clear whether patients with HD-induced hypoxia are more likely to develop critical condition or patients with critical COVID-19 develop HD-induced hypoxia, our results suggest that there is a close relationship between HD-induced hypoxia and the poor prognosis of COVID-19. Important limitations of our study include the small number of patients. In addition, we could not investigate the change of inflammatory markers such as IL-6 and activated complement during dialysis.

There is a close relationship among HD-induced hypoxemia and poor prognosis of COVID-19. The HDinduced hypoxemia of patients with COVID-19 may be caused by ventilation/perfusion mismatching.

Efficacy of the BNT162b2 mRNA Covid-19 Vaccine in a hemodialysis cohort

Immunological effects of a single hemodialysis treatment

Risk prediction of COVID-19 incidence and mortality in a large multi-national hemodialysis cohort: implications for management of the pandemic in outpatient hemodialysis settings

Immunopathogenesis and treatment of cytokine storm in COVID-19

Dynamic assessment of interleukin-6 during hemodialysis and mortality in coronavirus disease-19. Ther Apher Dial. 2021. • fast, convenient online submission • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year • At BMC, research is always in progress. Learn more biomedcentral.com/submissions Ready to submit your research Ready to submit your research ? Choose BMC

Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis

Intradialytic hypoxemia in chronic hemodialysis patients

Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study

COVID-19 infection: viral macro-and micro-vascular coagulopathy and thromboembolism/prophylactic and therapeutic management

The emerging threat of (micro) thrombosis in COVID-19 and its therapeutic implications

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Correlations between serum inflammatory markers and comorbidities in patients with endstage renal disease

Haemodialysis in diabetic patients modulates inflammatory cytokine profile and T cell activation status

COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain

COVID-19 in hemodialysis patients: a single-center experience in Istanbul

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Not applicable.

HD: Hemodialysis; COVID-19: Coronavirus disease 2019; DM: Diabetes mellitus; HFNC: High-flow nasal cannula; Aa-DO 2 : Alveolar-arterial oxygen pressure difference.

The online version contains supplementary material available at https:// doi. org/ 10. 1186/ s41100-022-00408-5.Additional file 1. Supplement Table 1 . Clinical information of all patients hospitalized with COVID-19.

AY and MR designed for this study. MT and AY collected the clinical information. MT and AY analyzed the data and drafted the manuscript. All authors revised the paper, and all authors approved the final version of the manuscript.

No funding or sponsorship was received for this study or publication of this article.

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

The research ethics committee of the Tokyo Saiseikai Central Hospital evaluated and approved the study protocol (approval number 2021-007-01). As the present study was a retrospective and non-interventional study, an opt-out method was adopted. We provided patients an opportunity to opt out by explaining this study on our website.

Not applicable.

The authors declare that they have no competing interests.Received: 18 January 2022 Accepted: 1 May 2022